Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population

Background and Objective: Cyclins are the key regulator of the cell cycle and their over-expression has been seen in many cancers including breast cancer. Cyclin D1 is an oncoprotein encoded by CCND1 gene located on chromosome 11 (11q) which regulates cell cycle in shifting from G1 to S phase. It’s...

Full description

Bibliographic Details
Main Authors: Khosrow Keshavarz Safiei, Farhad Mashayekhi, Hamid Saeidi saedi
Format: Article
Language:English
Published: "Alexandru Ioan Cuza" University of Iași 2024-03-01
Series:Journal of Experimental and Molecular Biology
Subjects:
Online Access:http://www.jemb.bio.uaic.ro/index.php/jemb/article/view/153
_version_ 1797260173043040256
author Khosrow Keshavarz Safiei
Farhad Mashayekhi
Hamid Saeidi saedi
author_facet Khosrow Keshavarz Safiei
Farhad Mashayekhi
Hamid Saeidi saedi
author_sort Khosrow Keshavarz Safiei
collection DOAJ
description Background and Objective: Cyclins are the key regulator of the cell cycle and their over-expression has been seen in many cancers including breast cancer. Cyclin D1 is an oncoprotein encoded by CCND1 gene located on chromosome 11 (11q) which regulates cell cycle in shifting from G1 to S phase. It’s the main target for steroids and mitogenic growth hormones in breast epithelial cells. This study aimed to evaluate the relationship between Cyclin D1 G870A polymorphism and breast cancer risk in a population in the north of Iran. Methods: Whole blood samples collected from 82 patients with breast cancer and 66 healthy women. DNA was extracted and genotyping was performed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) technique. Results: Genotypic prevalence of AA, AG, GG genotypes among patients were 40.2%, 35.3% and 24.4% and in controls were 30%, 47%, 23%, respectively. There was no significant difference in CCND1 G870A genotype polymorphism between patients and control group (p=0.32). Also, allelic prevalence of A and G alleles in breast cancer patients were 58% and 42%, in controls were 54% and 46%, respectively. The present study showed that there is no significant association between CCND1 G870A polymorphism with the risk of breast cancer. Conclusion: The results of this study revealed that there is no significant association between CCND1 G870A genetic polymorphism and the risk of breast cancer in the population of the north of Iran. More studies with larger samples of cases and controls would be beneficial.
first_indexed 2024-04-24T23:21:06Z
format Article
id doaj.art-eeec617c0c004c4eac80302701b31027
institution Directory Open Access Journal
issn 2601-6974
language English
last_indexed 2024-04-24T23:21:06Z
publishDate 2024-03-01
publisher "Alexandru Ioan Cuza" University of Iași
record_format Article
series Journal of Experimental and Molecular Biology
spelling doaj.art-eeec617c0c004c4eac80302701b310272024-03-16T11:02:24Zeng"Alexandru Ioan Cuza" University of IașiJournal of Experimental and Molecular Biology2601-69742024-03-0110.47743/jemb-2024-153Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian populationKhosrow Keshavarz Safiei0Farhad MashayekhiHamid Saeidi saedi Department of Genetics Background and Objective: Cyclins are the key regulator of the cell cycle and their over-expression has been seen in many cancers including breast cancer. Cyclin D1 is an oncoprotein encoded by CCND1 gene located on chromosome 11 (11q) which regulates cell cycle in shifting from G1 to S phase. It’s the main target for steroids and mitogenic growth hormones in breast epithelial cells. This study aimed to evaluate the relationship between Cyclin D1 G870A polymorphism and breast cancer risk in a population in the north of Iran. Methods: Whole blood samples collected from 82 patients with breast cancer and 66 healthy women. DNA was extracted and genotyping was performed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) technique. Results: Genotypic prevalence of AA, AG, GG genotypes among patients were 40.2%, 35.3% and 24.4% and in controls were 30%, 47%, 23%, respectively. There was no significant difference in CCND1 G870A genotype polymorphism between patients and control group (p=0.32). Also, allelic prevalence of A and G alleles in breast cancer patients were 58% and 42%, in controls were 54% and 46%, respectively. The present study showed that there is no significant association between CCND1 G870A polymorphism with the risk of breast cancer. Conclusion: The results of this study revealed that there is no significant association between CCND1 G870A genetic polymorphism and the risk of breast cancer in the population of the north of Iran. More studies with larger samples of cases and controls would be beneficial. http://www.jemb.bio.uaic.ro/index.php/jemb/article/view/153Breast cancer; ccnd1; polymorphism
spellingShingle Khosrow Keshavarz Safiei
Farhad Mashayekhi
Hamid Saeidi saedi
Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
Journal of Experimental and Molecular Biology
Breast cancer; ccnd1; polymorphism
title Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
title_full Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
title_fullStr Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
title_full_unstemmed Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
title_short Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
title_sort cyclin d1 g870a polymorphism and breast cancer risk in an iranian population
topic Breast cancer; ccnd1; polymorphism
url http://www.jemb.bio.uaic.ro/index.php/jemb/article/view/153
work_keys_str_mv AT khosrowkeshavarzsafiei cyclind1g870apolymorphismandbreastcancerriskinaniranianpopulation
AT farhadmashayekhi cyclind1g870apolymorphismandbreastcancerriskinaniranianpopulation
AT hamidsaeidisaedi cyclind1g870apolymorphismandbreastcancerriskinaniranianpopulation